Vericel Co. (NASDAQ:VCEL - Get Free Report) Director Robert L. Md Zerbe sold 3,278 shares of the business's stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total value of $169,046.46. Following the completion of the sale, the director now owns 23,395 shares of the company's stock, valued at $1,206,480.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Vericel Stock Down 0.6 %
Shares of VCEL stock opened at $52.02 on Friday. Vericel Co. has a 12 month low of $28.02 and a 12 month high of $52.50. The firm has a market cap of $2.52 billion, a PE ratio of -578.00 and a beta of 1.69. The stock has a 50 day moving average of $45.97 and a 200-day moving average of $38.86.
Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.08. The business had revenue of $65.00 million for the quarter, compared to analysts' expectations of $64.28 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. Vericel's quarterly revenue was up 23.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.12 earnings per share. As a group, equities analysts predict that Vericel Co. will post 0.09 EPS for the current fiscal year.
Institutional Trading of Vericel
He Is Giving Away Bitcoin
From Crypto Swap Profits | Ad
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously.
Right now is a very important time to pay attention to what we are doing and what is happening.
If you wait... it will be too late.
This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
>> Register right here
A number of institutional investors and hedge funds have recently modified their holdings of the company. Gamco Investors INC. ET AL increased its position in shares of Vericel by 1.9% during the second quarter. Gamco Investors INC. ET AL now owns 17,510 shares of the biotechnology company's stock valued at $658,000 after purchasing an additional 325 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Vericel by 8.1% during the third quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company's stock valued at $154,000 after purchasing an additional 344 shares during the period. LPL Financial LLC increased its position in shares of Vericel by 6.6% during the second quarter. LPL Financial LLC now owns 8,348 shares of the biotechnology company's stock valued at $314,000 after purchasing an additional 518 shares during the period. Gotham Asset Management LLC increased its position in shares of Vericel by 3.6% during the third quarter. Gotham Asset Management LLC now owns 15,311 shares of the biotechnology company's stock valued at $513,000 after purchasing an additional 538 shares during the period. Finally, State of Wyoming grew its position in Vericel by 23.8% in the fourth quarter. State of Wyoming now owns 3,025 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 581 shares during the period.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. HC Wainwright boosted their target price on Vericel from $46.00 to $53.00 and gave the stock a "buy" rating in a report on Friday, March 1st. Truist Financial reiterated a "buy" rating and set a $54.00 price target on shares of Vericel in a report on Tuesday. Finally, TheStreet upgraded Vericel from a "d+" rating to a "c-" rating in a report on Monday, January 29th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $46.40.
Get Our Latest Analysis on VCEL
About Vericel
(
Get Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
